Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Dec 4, 2013 12:22 PM Flag

    BMY for VRTX chatter

    This could be a match made in heaven.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • johnf50@rocketmail.com johnf50 Dec 4, 2013 4:24 PM Flag

      Well I guess you got the thumbs down because of a superficial understanding of what you are actually saying.

      I agree with you though - but I don't believe it will happen. Partnership more likely and would be a great boon for Vertex.

      Thumbs up.

      Sentiment: Hold

      • 1 Reply to johnf50
      • JF, they are already partners in 135+Daclatasvir, but you are right; an outright buyout would not happen unless VRTX fails in all drug development. As I said before, VX-135 and Ribavirin are antagonistic, and didn't give meaningful SVRs, but Daclatasvir is an outstanding NS5A inhibitor and it must be a good partner drug for VX-135. The SVR12 has to be 90% or better for all viral genotypes in a dosing duration of 12 weeks or less, and the combo has to be safe and very well tolerated, if the partnership with Bristol is going to continue. If the combo works out, Vertex should consider buying Daclatasvir from Bristol. Bristol is no longer developing Hep C drugs in order to concentrate on oncology drugs.

 
VRTX
82.00-4.61(-5.32%)Feb 8 4:00 PMEST